World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
95
Citations
55709
World Ranking
871
National Ranking
484

Taha Merghoub publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Taha Merghoub sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 448 publications — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Taha Merghoub D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Taha Merghoub sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 95 D-Index — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Taha Merghoub is affiliated with Cornell University in the United States. Their research focuses primarily on the interface of medicine, biochemistry, genetics, molecular biology, immunology, and microbiology. Within these broad fields, they have a substantial body of work relating to oncology, immunology, molecular biology, cancer research, and pulmonary and respiratory medicine.

The scientist's main research topics include:

  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • Immune cells in cancer
  • Immune Cell Function and Interaction
  • Cancer, Hypoxia, and Metabolism
  • Cancer Genomics and Diagnostics

Taha Merghoub has published extensively in a range of scientific journals and venues. The most frequent publication venues for their work are:

  • Cancer Research
  • Regular and Young Investigator Award Abstracts
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Nature
  • Journal of Clinical Oncology

Among their recent papers are:

  • "Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer" (2023) published in Nature
  • "Consensus guidelines for the definition, detection and interpretation of immunogenic cell death" (2020) published in Journal for ImmunoTherapy of Cancer
  • "Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways" (2021) published in Nature Reviews Clinical Oncology
  • "Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors" (2021) published in Immunity
  • "CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors" (2020) published in Nature Immunology

The scientist has also contributed to academic books, including the publication "Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer" in 2021 through Frontiers Media.

Frequent co-authors in their research include:

  • Jedd D. Wolchok
  • Sadna Budhu
  • Roberta Zappasodi
  • Levi Mangarin
  • Cailian Liu

Best Publications

  • Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

    Naiyer A. Rizvi;Naiyer A. Rizvi;Matthew D. Hellmann;Matthew D. Hellmann;Alexandra Snyder;Alexandra Snyder;Pia Kvistborg

  • Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

    Alexandra Snyder;Vladimir Makarov;Taha Merghoub;Jianda Yuan

  • Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

    Nicholas McGranahan;Nicholas McGranahan;Andrew J. S. Furness;Rachel Rosenthal;Sofie Ramskov

  • Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

    Patrick M. Forde;Jamie E. Chaft;Kellie N. Smith;Valsamo Anagnostou

  • Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

    Katherine B. Chiappinelli;Pamela L. Strissel;Alexis Desrichard;Huili Li

  • Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

    Hira Rizvi;Francisco Sanchez-Vega;Konnor La;Walid Chatila

  • Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

    Unknown

  • Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.

    Vinod P. Balachandran;Marta Łuksza;Julia N. Zhao;Vladimir Makarov

  • Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

    Matthew D. Hellmann;Tavi Nathanson;Hira Rizvi;Benjamin C. Creelan

  • Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

    Lorenzo Galluzzi;Ilio Vitale;Sarah Warren;Sandy Adjemian

  • Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

    Sergio A. Quezada;Tyler R. Simpson;Karl S. Peggs;Taha Merghoub

  • Chromatin states define tumour-specific T cell dysfunction and reprogramming

    Mary Philip;Lauren Fairchild;Lauren Fairchild;Liping Sun;Ellen L. Horste

  • Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

    Olivier De Henau;Matthew Rausch;David Winkler;Luis Felipe Campesato

  • Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways.

    Lukas Kraehenbuehl;Chien-Huan Weng;Shabnam Eghbali;Jedd D Wolchok

  • Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy

    Dmitriy Zamarin;Dmitriy Zamarin;Rikke B. Holmgaard;Rikke B. Holmgaard;Sumit K. Subudhi;Joon Seok Park;Joon Seok Park

  • Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.

    J.C. Osorio;A. Ni;J.E. Chaft;R. Pollina

  • Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors.

    Shihao Xu;Omkar Chaudhary;Patricia Rodríguez-Morales;Xiaoli Sun

  • A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy

    Marta Łuksza;Nadeem Riaz;Vladimir Makarov;Vinod P. Balachandran

  • Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas

    Piro Lito;Christine A. Pratilas;Eric W. Joseph;Madhavi Tadi

  • CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors

    Haiping Wang;Fabien Franco;Yao Chen Tsui;Xin Xie

  • Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies

    Roberta Zappasodi;Taha Merghoub;Jedd D. Wolchok

  • Role of the proto-oncogene Pokemon in cellular transformation and ARF repression

    Takahiro Maeda;Robin M. Hobbs;Taha Merghoub;Ilhem Guernah

  • Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner

    Rikke B. Holmgaard;Dmitriy Zamarin;Yanyun Li;Billel Gasmi

  • Erratum: Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses (Cell (2015) 152 (974-986))

    Katherine B. Chiappinelli;Pamela L. Strissel;Alexis Desrichard;Huili Li

Frequent Co-Authors

Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Matthew D. Hellmann
Matthew D. Hellmann Memorial Sloan Kettering Cancer Center
Alan N. Houghton
Alan N. Houghton Memorial Sloan Kettering Cancer Center
Stewart Shuman
Stewart Shuman Memorial Sloan Kettering Cancer Center
Pier Paolo Pandolfi
Pier Paolo Pandolfi Beth Israel Deaconess Medical Center
Timothy A. Chan
Timothy A. Chan Cleveland Clinic
Neal Rosen
Neal Rosen Memorial Sloan Kettering Cancer Center
David B. Solit
David B. Solit Memorial Sloan Kettering Cancer Center
Michael A. Postow
Michael A. Postow Memorial Sloan Kettering Cancer Center
Katherine S. Panageas
Katherine S. Panageas Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing advanced nursing degrees such as the Psychiatric Mental Health Nurse Practitioner (PMHNP) can be a valuable pathway. Many aspiring professionals seek out top pmhnp programs that offer strong clinical placement rates, ensuring hands-on experience critical to career success.

Affordability is another key consideration when choosing a program. Students can explore some of the cheapest pmhnp programs online without sacrificing quality, making advanced education more accessible.

Career prospects and salary expectations are also important. For example, knowing how much does a dnp make can help in planning your financial future and assessing the return on investment of your education.

Additionally, transitioning specializations can expand your opportunities. Nurses looking to move from a Family Nurse Practitioner (FNP) role to more acute settings might consider acute care certification for fnp, which enhances skills and opens doors to new career pathways.

Best Scientists Citing Taha Merghoub

Trending Scientists

Recently Published Articles